Skip to main content
. Author manuscript; available in PMC: 2023 Jun 18.
Published in final edited form as: Surg Oncol Clin N Am. 2022 Oct;31(4):569–579. doi: 10.1016/j.soc.2022.06.001

Fig. 3.

Fig. 3.

Patient with left breast palpable ER-positive HER2-negative ILC with de novo stage IV disease. Panel A shows FDG-PET with uptake at known left breast mass. (B, C) show 18-F FES PET demonstrating foci of low-level avidity on rewindowing images for higher sensitivity, consistent with bone metastases. Bone metastases in sternum and iliac crest denoted by red arrows.